It’s been a torrid first half for Aegerion Pharmaceuticals that began the year with a 25% cut to its staff, but the biotech is swinging the ax again--this time…

Gene therapy player AveXis has gotten a Breakthrough Therapy Designation for its only clinical candidate, AVXS-101 to treat spinal muscular atrophy Type 1.

Zafgen fell about 40% in after-hours trading on news that it has suspended development of its lead obesity candidate beloranib, which had been on a clinical…

An FDA advisory committee recommended that the agency approve Valeant’s brodalumab to treat moderate-to-severe plaque psoriasis.

One of AstraZeneca’s key drugs for its ambitious sales target Tagrisso (osimertinib) has hit its marks in a Phase III test for certain lung cancer patients--…

George Freeman has left the post of minister for life sciences as part of a reshuffle initiated by the new U.K. prime minister in the wake of the Brexit vote.

Another day, another unanimous FDA panel vote, this time recommending Novartis’ Enbrel (etanercept) biosimilar be approved across all of its U.S. licenses.

Kite Pharma has said it has no concerns with its recently enrolled experimental CAR-T trial that is using a chemo drug now dropped by rival Juno after it…